The nation of Zimbabwe has declined a major American healthcare agreement worth $367m (£272m) spanning five years due to Washington's request for sensitive biological samples.
This rejection was revealed after a government memo dated December was leaked, indicating that President Emmerson Mnangagwa felt the arrangement was "unbalanced".
A government spokesman has since explained that the US was requesting genetic material for research and profit while was unwilling to share the benefits from future treatments.
"We must now begin the difficult and regrettable process of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had donated over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued dialogue to secure a deal suitable to both sides so the country's critical HIV programme can be sustained.
Wider Context
This development follows a comparable case in Kenya, where a high court halted a related deal with the US after legal challenges were filed about the safety of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
The agency had administered assistance for the US government, but Trump argued its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance transparency and accountability.
Based on reports, Sixteen African countries have to date agreed to these new agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The funds for Zimbabwe would have supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any corresponding guarantee of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens should a new health crisis arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting systems previously set up via the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This system is designed to guarantee that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing discussions with our American counterparts on how subsequent co-operation might be arranged in a way that respects the sovereignty and interests of both nations."
Health Experts Reaction
Medical experts stated it acknowledged the government's concerns, but recommended that talks must proceed considering much of the country's Aids initiatives depended on external financing.
"In cases where specific concerns exist, including those relating to information security or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the ongoing debate between receiving vital international aid and protecting local interests in an ever more data-driven world.